Principal Investigator: Richard Shaw
Trial Coordinator: Matt Bickerstaff
Contact: Email not available without JavaScript
Tel: 0151 794 8934

Aim: Patients who have received radiotherapy to their jaws during treatment for head and neck cancer are at risk of a condition called osteoradionecrosis, often requiring prolonged and complex surgical treatment. This study measures the value of high pressure oxygen therapy in reducing this risk.

Funding: CRUK FSC

Opened: 09/2008

Phase: phase III

Recruitment Target: 200 by 05/2014

Milestones:

CTAAC phase III funding application Dec 2009

DMC Meeting Dec 2009

TSG Meeting Feb 2010

Phase III funding award granted by CR-UK, May 2010

Randomised controlled unblinded multi-centre phase III trial of neo-adjuvant induction chemotherapy

Principal Investigator: Richard Shaw
Trial Coordinator: Email not available without JavaScript

Aim: TITAN addresses the potential survival advantage of TPF-induced chemotherapy (T - taxane, P - platinum, F - fluorouracil) prior to surgery and radiotherapy for locally advanced, resectable, squamous cell carcinoma of the head and neck.

Funding: CRUK FSC
Opened: due Q3 2010
Phase: feasibility for phase III
Recruitment Target: 50 by Q3 2012

Milestones:

NCRI CSG support  2009

FSC funding confirmed Dec09

Trial Co-ordinator appointed Oct 2010

Ethical & MHRA Approval July 2011

Trial Opening – rolling out from October 2011

LIHNCS: Lugol’s Iodine in Head and Neck Cancer Surgery

A multi-centre, randomised controlled trial assessing the effectiveness of Lugol’s Iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma insitu at mucosal resection margin of oral and oropharyngeal squamous cell carcinoma.

Principal Investigator: Jim McCaul
Trial Coordinator: Jacqueline Quantrill
Contact: Email not available without JavaScript
Tel: 01274 383921

Aim: This study is looking at whether the use of Lugol’s Iodine solution as a staining technique to detect dysplasia, helps reduce the incidence of dysplasia at resection margins in the surgical management of oral and oropharyngeal carcinoma and whether this in turn leads to a reduced risk of recurrence.

Funding: CRUK CTAAC
Opened: Oct 2010
Phase: Phase III
Recruitment Target: 300 by Nov 2013

Recruited 419 by Nov 2013

Milestones:

Funding confirmed Apr 2010

Ethics Approval Aug 2010

First  site opened Oct 2010

First patient recruited Nov 2010

Ethics approval - Extension of trial from 300 patients to 419 patients – July 2013

Last  site opened Aug 2013

Last patient recruited Nov 2013

Ethics approval extension of follow up to 5 years  July 2015

CLINICAL COHORT IN HEAD AND NECK CANCER

Principal investigator: Professor Andy Ness
Trial co-ordinator: Christine Wood
Contact: Email not available without JavaScript
Tel: 0117 342 2519 

Aim: To describe the social, lifestyle & clinical features of individuals with head and neck cancer and relate these to outcomes (in terms of morbidity, mortality and quality of life) and to examine the impact of different models of care on outcome and cost of care.

Funding: NIHR grant RP-PG-0707-10034
Recruitment Opened: 04/2011
Recruitment Target: 5000 by 12/2014